A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

By P. Flood-Page, C. Swenson, I. Faiferman, J. Matthews, Michael Williams, L. Brannick, D. Robinson, Sally E. Wenzel, W. Busse, T. Hansel and 1 more. American Journal of Respiratory and Critical Care Medicine, 2007

730 citations recorded by the source corpus.

Subfields: Physiology, Sociology and Political Science, Surgery

View Paper: https://www.semanticscholar.org/paper/b605c5062a36005349abfd4e6b0e09d0683e4188

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. P. Barnes
2. J. Fahy
3. Sally E. Wenzel
4. Ian M. Adcock
5. J. Arron
6. S. Holgate
7. Riccardo Polosa

In Sociology and Political Science

1. Sally E. Wenzel
2. P. Barnes

In Surgery

1. P. Barnes
2. J. Fahy
3. J. Arron
4. S. Holgate
5. Sally E. Wenzel

Citations in the corpus

• Mepolizumab treatment in patients with severe eosinophilic asthma. (2014, neutral): “Injection-site reaction 6 (3) 5 (3) 17 (9)”
• T-helper type 2-driven inflammation defines major subphenotypes of asthma. (2009, positive): “Residual IL-13 activity may therefore explain the incomplete tissue depletion of eosinophils observed in previous clinical trials of IL-5 blockade in asthma (37, 38).”
• Treatment strategies for allergy and asthma (2008, result): “, an observation that has recently been confirmed in a large trial with mepolizuma”
• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (2013, background): “While the anti-IL5 antibody, mepolizumab, was not beneficial in unselected adult patients with moderate asthma [321], when studied in severe asthma patients with persistent sputum”
• The cytokine network in asthma and chronic obstructive pulmonary disease. (2008, background): “In symptomatic asthmatics, mepolizumab has no clinical benefit, despite a marked reduction in circulating eosinophils (17).”
• Immunology of asthma and chronic obstructive pulmonary disease (2008, background): “The functional role of eosinophils in asthma is not clear and the evidence that links their presence to airway hyper-responsiveness has been questioned by the finding that the administration of IL-5-specific blocking antibodies that markedly reduce the number of eosinophils in the blood and sputum d”